GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (STU:6ML0) » Definitions » Retained Earnings

Molecular Partners AG (STU:6ML0) Retained Earnings : €-247.25 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Molecular Partners AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Molecular Partners AG's retained earnings for the quarter that ended in Sep. 2024 was €-247.25 Mil.

Molecular Partners AG's quarterly retained earnings declined from Mar. 2024 (€-207.58 Mil) to Jun. 2024 (€-223.09 Mil) and declined from Jun. 2024 (€-223.09 Mil) to Sep. 2024 (€-247.25 Mil).

Molecular Partners AG's annual retained earnings increased from Dec. 2021 (€-241.14 Mil) to Dec. 2022 (€-129.48 Mil) but then declined from Dec. 2022 (€-129.48 Mil) to Dec. 2023 (€-203.33 Mil).


Molecular Partners AG Retained Earnings Historical Data

The historical data trend for Molecular Partners AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Retained Earnings Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -119.87 -180.59 -241.14 -129.48 -203.33

Molecular Partners AG Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -177.93 -203.33 -207.58 -223.09 -247.25

Molecular Partners AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Molecular Partners AG  (STU:6ML0) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Molecular Partners AG Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG Headlines

No Headlines